Cardinal Health Inc. ($CAH) Stock Forecast: Up 6.3% Today

What is Cardinal Health Inc.?

Cardinal Health Inc. (CAH) is a healthcare services company that focuses on pharmaceutical distribution and medical products. Today, CAH experienced a strong bullish movement in the stock market.

Why is Cardinal Health Inc. going up?

CAH stock is up 6.3% on Jun 10, 2026 13:50

• Cardinal Health Inc. (CAH) stock outperformed competitors and the overall market with a 4.01% increase, showcasing strong trading activity.
• The positive movement could be attributed to investor confidence in the company's performance and potential growth prospects in the healthcare sector.
• While Cardinal Health Inc. remains below its 52-week high, the bullish movement indicates a positive sentiment towards the company's future outlook and financial performance.
• The news surrounding other companies such as Vertex Pharmaceuticals, Onconetix, and Mission Produce, Inc. did not have a direct impact on CAH's market movement today.

CAH Price Chart

CAH Technical Analysis

CAH News

Cardinal Health Inc. stock outperforms competitors on strong trading day

Cardinal Health Inc. (CAH) stock rose 4.01% to $212.67 on Tuesday, outperforming a mixed stock market. The Dow Jones Industrial Average saw a slight increase, while the S&P 500 Index declined. Despite the gain, Cardinal Health Inc. remains 8.96% below its 52-week high.

https://www.marketwatch.com/data-news/cardinal-health-inc-stock-outperforms-competitors-on-strong-trading-day-4010dedd-36ba7bdbf1ac?mod=mw_quote_news

Can Vertex Pharmaceuticals Deepen Its Cystic Fibrosis Edge?

Vertex Pharmaceuticals is strengthening its position in the cystic fibrosis market through new pediatric ALYFTREK data, TRIKAFTA regulatory progress, and ongoing pipeline diversification. The company's future growth hinges on regulatory decisions, pediatric label language, safety updates, and broader pipeline advancements. These developments are key to extending its competitive edge in healthcare.

https://kalkinemedia.com/us/stocks/healthcare/can-vertex-pharmaceuticals-deepen-its-cystic-fibrosis-edge

Onconetix (ONCO) files S-1 for 100M-share Keystone equity line amid going-concern risks

Onconetix (ONCO) has filed an S-1 registration statement for a potential 100 million share equity line of credit with Keystone Capital Partners, intended for resale, despite having only 3.69 million shares outstanding, indicating severe potential dilution for existing shareholders. The company disclosed substantial doubt about its ability to continue as a going concern, reporting a $15.5 million net loss in 2025 and an accumulated deficit of $135.4 million, with cash balances of $3.7 million at March 31, 2026, and $6.5 million at June 5, 2026. Onconetix is focusing on commercializing its prostate cancer diagnostic test, Proclarix, and has a pending share exchange agreement with Realbotix Corp. which could transfer 75-90% of fully diluted ownership, depending on net cash.

https://www.stocktitan.net/sec-filings/ONCO/s-1-onconetix-inc-files-ipo-registration-statement-4a96e524fe52.html

Earnings Flash (AVO) Mission Produce, Inc. Reports Q2 Revenue $290.9M, vs. FactSet Est of $256.3M

Mission Produce, Inc. (AVO) reported Q2 revenue of $290.9 million, surpassing FactSet's estimate of $256.3 million. This financial update indicates a stronger-than-expected revenue performance for the company during the second quarter. The report highlights the company's financial results and provides context against analyst expectations.

https://www.marketscreener.com/news/earnings-flash-avo-mission-produce-inc-reports-q2-revenue-290-9m-vs-factset-est-of-256-3m-ce7f5dd3da8bf025

[144] CARDINAL HEALTH INC SEC Filing

This article announces an SEC Form 144 filing by Cardinal Health Inc. (CAH), indicating a proposed sale of securities under Rule 144. The filing provides details about the securities to be sold, including their acquisition date, nature of acquisition (restricted stock vesting), and the number of shares. This report is categorized as neutral in both impact and sentiment.

https://www.stocktitan.net/sec-filings/CAH/144-cardinal-health-inc-sec-filing-d2e95b25fd75.html

Trending Today

Align Technology Inc. ($ALGN) Stock Forecast: Up 5.2% Today

Grab Holdings Limited ($GRAB) Stock Forecast: Up 7.1% Today

Electronic Arts Inc. ($EA) Stock Forecast: Down 0.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 5.0% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.1% Today

Reddit Inc ($RDDT) Stock Forecast: Up 5.0% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.6% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 5.2% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Up 5.6% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Up 5.3% Today

Cardinal Health Inc. Price History

22.03.2026 - CAH Stock was down 4.5%

• Cardinal Health (CAH) stock experienced a significant bearish movement, falling by 2.96%.
• Despite analysts' positive expectations for the earnings report, the market reacted negatively to the stock.
• The underperformance of CAH compared to competitors and broader market indices suggests that investors may have had higher expectations for the company's performance.
• The upcoming earnings report will be crucial in determining if the stock can regain its momentum and reverse the bearish trend.

13.00.2026 - CAH Stock was up 5.2%

• Following an upward trend, Cardinal Health's stock witnessed a surge subsequent to the company's revision of its fiscal-year guidance and its forecast of specialty revenue surpassing $50 billion for 2026.
• The optimistic projections for 2026, fueled by successful strategic moves like alterations in Medicare Drug Prices and alliances with Publix Super Markets, played a significant role in driving the stock's upward trajectory.
• Launches such as the ContinuCare™ Pathway program for diabetes supply management, coupled with strong performance across operational sectors, underscored the company's substantial strategic advancement.
• In essence, Cardinal Health's favorable forecasts and strategic endeavors have bolstered investors' confidence, thereby propelling the bullish trend in the stock market.

08.00.2026 - CAH Stock was down 3.0%

• The recent decline in CAH stock price could be linked to profit-taking by investors following a previous increase in value.
• Although Cardinal Health delivered impressive Q3 earnings that exceeded analyst expectations, market sentiment or profit-related concerns may have driven the stock lower.
• An increased investment by Robeco Institutional Asset Management B.V. initially inspired confidence in the stock, but prevailing market conditions may have overshadowed this development.
• Investor focus on the strong performance and growth potential of McKesson in the healthcare sector may have diverted attention from Cardinal Health, impacting its stock performance unfavorably.

05.01.2026 - CAH Stock was up 7.7%

• CAH surpassed analyst projections in its second-quarter earnings, leading to a rise in its stock value.
• The company adjusted its full-year earnings forecast upward for the second time, showing strong confidence in its future business performance.
• The robust results and achievement of a new 52-week high were driven by the strong performance in its Pharmaceutical and Specialty Solutions division.
• Investor sentiment towards CAH is optimistic, as analysts hold a consensus "Strong Buy" rating with potential for increased gains, reflecting confidence in the company's future growth.

05.01.2026 - CAH Stock was up 7.3%

• Today, Cardinal Health (CAH) witnessed a notable uptrend following the announcement of exceptional Q4 CY2025 results that outperformed market predictions.
• The company's strong financial showing was fueled by a substantial increase in revenue, surpassing analyst forecasts by a significant margin.
• Cardinal Health adjusted its full-year EPS guidance upwards, indicating optimism in its strategic efforts and the strong industry momentum in healthcare distribution.
• The upsurge in demand for specialty drugs and the company's foray into high-profit markets were key drivers in the positive outlook and the heightened profitability projections, further instilling investor confidence in Cardinal Health's future prospects.

05.01.2026 - CAH Stock was up 9.4%

• Cardinal Health's robust growth momentum, driven by strong utilization and successful acquisitions, has led to an impressive earnings report that surpassed analyst expectations.
• The company's consistent guidance hikes and increased fiscal-year earnings guidance have instilled confidence in investors, resulting in a surge in the stock price.
• Cardinal Health's focus on strategic initiatives and solid financial performance, including a significant increase in sales and adjusted earnings, has propelled the stock to reach a new 52-week high.
• The positive market sentiment towards Cardinal Health is further fueled by the CEO's explanation of the factors contributing to the company's success, reinforcing investor optimism in the stock's future prospects.

30.03.2026 - CAH Stock was down 5.6%

• Cardinal Health (CAH) reported strong third-quarter fiscal year 2026 results, with revenue increasing by 11% to $60.9 billion and non-GAAP diluted EPS rising by 35% to $3.17, but experienced a bearish market movement.
• The bearish movement followed the company missing revenue forecasts, posting $60.94 billion against an expected $62.35 billion, despite surpassing Wall Street's expectations for adjusted earnings.
• The market's response may have been influenced by the revenue miss overshadowing the positive earnings beat and the company's raised outlook for fiscal year 2026 non-GAAP EPS guidance to $10.70 to $10.80.
• Concerns about the revenue shortfall and potential risks like drug pricing policies and vertical integration challenges could have contributed to the bearish sentiment towards Cardinal Health's stock.

10.05.2026 - CAH Stock was up 6.3%

• Cardinal Health Inc. (CAH) stock outperformed competitors and the overall market with a 4.01% increase, showcasing strong trading activity.
• The positive movement could be attributed to investor confidence in the company's performance and potential growth prospects in the healthcare sector.
• While Cardinal Health Inc. remains below its 52-week high, the bullish movement indicates a positive sentiment towards the company's future outlook and financial performance.
• The news surrounding other companies such as Vertex Pharmaceuticals, Onconetix, and Mission Produce, Inc. did not have a direct impact on CAH's market movement today.

12.01.2026 - CAH Stock was down 3.8%

• Cardinal Health (CAH) faced a downwards trend in the market today amid mixed earnings reports in the healthcare sector.
• Despite positive Q4 results and an increased annual outlook, concerns emerged during the earnings call regarding profit distribution, capital management, and the effects of market price adjustments.
• A general sense of caution in the healthcare industry, exemplified by other companies like Baxter International and QuidelOrtho, may have influenced the negative response to Cardinal Health's performance.
• Investors appear to be reassessing their healthcare investments, resulting in a decline in CAH shares, despite the company's strong financial standing.

30.03.2026 - CAH Stock was down 6.9%

• The stock dropped despite surpassing earnings expectations for the third quarter of 2026; however, revenue fell short of consensus estimates, leading to investor dissatisfaction.
• In the third quarter, the company showed strong performance with a 35% increase in non-GAAP diluted EPS and an 11% rise in revenue. Nonetheless, a 20% decrease in GAAP diluted EPS due to a goodwill impairment charge affected the overall perception.
• Despite an upward revision of its fiscal 2026 adjusted earnings and free cash flow guidance, the market responded unfavorably to the revenue miss, underscoring the significance of revenue performance in shaping investor outlook.
• The enhancement of Actinium-225 production capabilities in nuclear medicine might have been overshadowed by the revenue miss, contributing to the downward trend in Cardinal Health's stock.

04.01.2026 - CAH Stock was down 5.0%

• Cardinal Health revised its FY25 earnings forecast upwards, anticipating notable growth in EPS over the next three years, which should typically have a positive effect on the stock.
• Allianz Asset Management GmbH decreased its ownership in Cardinal Health by 30%, potentially indicating investor uncertainty or profit-taking, which could have contributed to the recent market decline.
• Despite the encouraging earnings forecast and solid segment performance, the market's response towards Cardinal Health appears to have been more influenced by the significant reduction in ownership by a major investor, leading to the recent downturn.
• Various factors such as the overall healthcare sector's performance and general market trends may have also impacted the recent bearish movement of Cardinal Health's stock.

14.04.2026 - CAH Stock was up 5.0%

• Despite a slight reduction in price targets by analysts, Cardinal Health's bullish movement can be attributed to its positive fiscal Q3 results, increased fiscal 2026 EPS guidance, and adjusted free cash flow outlook.
• The company's strong earnings beat, surpassing estimates and demonstrating operational strength, has instilled confidence in investors and addressed concerns about potential industry growth slowdowns.
• Cardinal Health's competitive position in pharmaceutical distribution, coupled with its diversified healthcare services, has positioned it well to capitalize on market opportunities and drive shareholder value.
• The bullish trend in CAH stock reflects investor optimism in the company's ability to navigate industry challenges, maintain its market leadership, and deliver sustained financial performance.